Literature DB >> 15027893

Nephrocalcinosis: molecular insights into calcium precipitation within the kidney.

John A Sayer1, Georgina Carr, Nicholas L Simmons.   

Abstract

Nephrocalcinosis may be defined as a generalized increase in the calcium content of the kidneys. This renal calcification may occur at a molecular, microscopic or macroscopic level leading to progressive amounts of renal damage. The major causes include those associated with an increase in urinary levels of calcium, oxalate and phosphate. Under these conditions, urine concentration and supersaturation leads to calcium crystal precipitation, which may be an intratubular event or initiate within the renal interstitium. The focus of discussion concerning renal calcification is often limited to factors that lead to renal stones (calculi and nephrolithiasis); however, nephrocalcinosis is a more sinister event, and often implies a serious metabolic defect. This review will discuss the hypotheses concerning initiating lesions of nephrocalcinosis using available laboratory and clinical studies and will examine whether new understanding of the molecular basis of tubulopathies, that lead to nephrocalcinosis, has given further insights.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027893     DOI: 10.1042/CS20040048

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  38 in total

1.  A multiphysics model of in vitro transcription coupling enzymatic reaction and precipitation formation.

Authors:  Satoru Akama; Masayuki Yamamura; Takanori Kigawa
Journal:  Biophys J       Date:  2012-01-18       Impact factor: 4.033

Review 2.  The tubular epithelium in the initiation and course of intratubular nephrocalcinosis.

Authors:  Benjamin A Vervaet; Anja Verhulst; Marc E De Broe; Patrick C D'Haese
Journal:  Urol Res       Date:  2010-08-02

3.  Cross-sectional study of kidney stones by laser-induced breakdown spectroscopy.

Authors:  V K Singh; A K Rai; P K Rai; P K Jindal
Journal:  Lasers Med Sci       Date:  2008-12-23       Impact factor: 3.161

4.  Intestinal permeability in subjects from two different race groups with diverse stone-risk profiles.

Authors:  Takalani Theka; Allen Rodgers; Neil Ravenscroft; Sonja Lewandowski
Journal:  Urolithiasis       Date:  2013-01-22       Impact factor: 3.436

5.  Laterality of nephrocalcinosis in kidney stone formers with severe hypocitraturia.

Authors:  Jesse D Le; Brian H Eisner; Timothy Y Tseng; Thomas Chi; Marshall L Stoller
Journal:  BJU Int       Date:  2011-01       Impact factor: 5.588

6.  Posttransplant nephrocalcinosis is associated with poor renal allograft function: a single-center experience.

Authors:  Abdul Moiz; Tariq Javed; Jorge Garces; Adriana Dornelles; Catherine Staffeld-Coit
Journal:  Ochsner J       Date:  2015

7.  Biomimetic Randall's plaque as an in vitro model system for studying the role of acidic biopolymers in idiopathic stone formation.

Authors:  Archana Chidambaram; Douglas Rodriguez; Saeed Khan; Laurie Gower
Journal:  Urolithiasis       Date:  2014-08-15       Impact factor: 3.436

8.  1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis.

Authors:  Galina Nesterova; May Christine Malicdan; Kaori Yasuda; Toshiyuki Sakaki; Thierry Vilboux; Carla Ciccone; Ronald Horst; Yan Huang; Gretchen Golas; Wendy Introne; Marjan Huizing; David Adams; Cornelius F Boerkoel; Michael T Collins; William A Gahl
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 8.237

9.  Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.

Authors:  Laurence Richard Solomon; Andrew Christopher Nixon; Leanne Ogden; Beena Nair
Journal:  BMJ Case Rep       Date:  2017-11-12

10.  Ultrasound is superior to computed tomography for assessment of medullary nephrocalcinosis in hypoparathyroidism.

Authors:  Alison M Boyce; Thomas H Shawker; Suvimol C Hill; Peter L Choyke; Michael C Hill; Robert James; Nancy A Yovetich; Michael T Collins; Rachel I Gafni
Journal:  J Clin Endocrinol Metab       Date:  2013-01-24       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.